Algorae Pharmaceuticals (ASX:1AI) is working with the Victorian Center for Functional Genomics (VCFG) at Peter MacCallum Cancer Center to validate artificial intelligence-predicted drug interactions through screening, according to a Thursday filing with the Australian bourse.
The study will assess 24 drug candidates using VCFG's advanced screening platform to confirm drug combinations' efficacy across four cancer cell lines, the filing said.
The data analysis is expected to be completed within three weeks of each screen run, with the full dataset expected to be completed within six months, per the filing.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。